PA
APLS

Perceptive Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Perceptive Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100,000
Closed -$72.5K – 104
2023
Q3 		$72.5K Buy
+100,000
New +$4.39M ﹤0.01% 92

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Perceptive Advisors's APLS Position: Q2 2026 in Review

Perceptive Advisors sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 80,956 shares — an estimated $3.26M sold.

Perceptive Advisors first reported a position in APLS in Q1 2020 and held it in 11 quarters. The position peaked at $75.3M in Q1 2022. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Perceptive Advisors reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Perceptive Advisors sold 80,956 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.26M.
  • Perceptive Advisors first reported a position in Apellis Pharmaceuticals in Q1 2020 and held it in 11 quarters.
  • Perceptive Advisors's Apellis Pharmaceuticals position peaked at $75.3M in Q1 2022.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.